BABAM2

BABAM2 (BRE/BRCC45) is a scaffold/adaptor protein that integrates two broad cellular programs: DNA-damage response and the control of receptor-triggered apoptosis (PMID:9737713, PMID:21282113). In the nucleus it is a shared component of two BRCC36-containing deubiquitinase complexes—the BRCA1-A and BRISC/ABRO1 complexes—where its C-terminal UEV domain binds NBA1/MERIT40, an interaction required for complex integrity, cellular resistance to ionizing radiation, and recruitment of BRCA1 to DNA damage sites for homologous-recombination repair (PMID:21282113, PMID:27001068). Through this DNA-damage axis BABAM2 also stabilizes the CDC25A phosphatase by recruiting the deubiquitylase USP7, opposing CDC25A degradation and permitting cell-cycle progression after damage; loss of BABAM2 causes G1 retention, CDC25A/CDK2 loss, and prolonged p53 activation (PMID:29416040, PMID:33050379). At the cell surface, BABAM2 was first identified as a binding partner of the TNFR1 juxtamembrane domain that dampens TNF-induced NF-κB signaling, and it additionally binds Fas to inhibit the mitochondrial apoptotic pathway downstream of death receptors, an antiapoptotic role confirmed in vivo by resistance of liver-specific transgenic mice to Fas-mediated hepatic apoptosis (PMID:9737713, PMID:15465831, PMID:17704801). BABAM2 further restrains apoptosis by maintaining XIAP protein and mRNA levels (PMID:24395041). The protein also participates in developmental and lineage programs: it promotes Mdm2-mediated p53 ubiquitination and degradation to favor osteoblast differentiation, suppresses osteoclastogenesis by interacting with Hey1 to inhibit Nfatc1 transcription, and supports satellite-cell migration during muscle regeneration by protecting CXCR4 from SDF-1α-induced degradation (PMID:28436570, PMID:35864959, PMID:26740569).

1. 1998 High

   Established the first molecular role of BABAM2 by identifying it as a TNFR1-associated factor that modulates death-receptor signaling, framing the protein as a regulator of cytokine signal transduction.

   Evidence Yeast two-hybrid, in vitro binding, Co-IP, and NF-κB reporter assay in mammalian cells

   PMID:9737713

   Open questions at the time

   • Did not define how BABAM2 binding alters downstream NF-κB components
   • No structural basis for the TNFR1 interaction
2. 2004 High

   Extended the receptor repertoire to Fas and localized BABAM2's antiapoptotic action to the mitochondrial pathway downstream of death receptors, establishing a stimulus-specific physiological role.

   Evidence Co-IP, siRNA knockdown, flow-cytometry apoptosis assays, and subcellular fractionation

   PMID:15465831

   Open questions at the time

   • Identity of the phospho/sumoylated/ubiquitinated partners engaged after receptor ligation not resolved
   • Mechanism of differential dissociation from TNFR1 versus Fas unknown
3. 2011 High

   Defined BABAM2 as a structural hub of both BRCC36 deubiquitinase complexes, showing its UEV-domain interaction with NBA1/MERIT40 is required for complex integrity and BRCA1 recruitment, unifying its DNA-damage role.

   Evidence Reciprocal Co-IP with deletion-based domain mapping, siRNA knockdown, clonogenic survival, and immunofluorescence

   PMID:21282113

   Open questions at the time

   • Catalytic contribution of BABAM2 to deubiquitination, if any, not established
   • How nuclear versus cytoplasmic complex assembly is partitioned unaddressed
4. 2016 Medium

   Confirmed in a clean knockout system that BABAM2 is required for BRCA1-A recruitment and HR repair, linking its loss to persistent damage signaling and premature senescence.

   Evidence BRE-/- fibroblasts with γ-H2AX foci imaging, SA-β-Gal assay, and gamma irradiation

   PMID:27001068

   Open questions at the time

   • Did not separate scaffold from any signaling function in senescence
   • Single cell type
5. 2018 High

   Identified a USP7/CDC25A axis showing BABAM2 stabilizes CDC25A by recruiting USP7, providing a mechanism by which it sustains cell-cycle progression in BRCA2-deficient cells.

   Evidence Insertional mutagenesis screen, Co-IP, ubiquitylation assay, and viability assays

   PMID:29416040

   Open questions at the time

   • Whether USP7 recruitment is independent of the BRCC36 complexes not clarified
   • Direct versus bridged BABAM2-USP7 contact undefined
6. 2020 Medium

   Demonstrated in mESCs that BABAM2 loss couples DNA damage to G1 retention, CDC25A/CDK2 degradation, prolonged p53 activity, and Nanog suppression, connecting its cell-cycle role to pluripotency control.

   Evidence Babam2-knockout mESCs with cell-cycle flow cytometry and immunoblotting after irradiation/doxorubicin

   PMID:33050379

   Open questions at the time

   • Causal chain from CDC25A loss to Nanog suppression not fully dissected
   • Stem-cell-specific factors not separated from general mechanism
7. 2014 Medium

   Showed BABAM2 maintains XIAP at both mRNA and protein levels, providing an additional route by which it confers broad apoptotic resistance to death-receptor and genotoxic stimuli.

   Evidence shRNA depletion with reconstitution, immunoblot, RT-PCR, apoptosis assays, and protein turnover assays

   PMID:24395041

   Open questions at the time

   • Molecular mechanism of XIAP transcriptional control unidentified
   • Direct versus indirect regulation not distinguished
8. 2007 Medium

   Validated the antiapoptotic function in vivo, showing liver-specific BABAM2 transgenic mice resist Fas-mediated lethal hepatic apoptosis.

   Evidence Liver-specific transgenic mice in a Fas-induced hepatitis model with survival analysis and IHC

   PMID:17704801

   Open questions at the time

   • Did not map the in vivo molecular effectors
   • Post-transcriptional regulation of BABAM2 in liver mechanistically unexplained
9. 2017 Medium

   Connected BABAM2 to the p53/Mdm2 axis in skeletal lineage cells, showing it promotes Mdm2-mediated p53 degradation to enable osteoblast differentiation.

   Evidence siRNA/overexpression, Co-IP for BABAM2-p53 interaction, p53 ubiquitination assay, and osteogenesis assays in vitro and in vivo

   PMID:28436570

   Open questions at the time

   • Whether BABAM2 directly stimulates Mdm2 activity or merely scaffolds unknown
   • Relationship to its DNA-damage p53 effects not reconciled
10. 2022 Medium

    Established BABAM2 as a negative regulator of osteoclastogenesis acting through a Hey1-Nfatc1 transcriptional axis, supported by transgenic mice with increased bone mass.

    Evidence Co-IP for BABAM2-Hey1 interaction, transgenic mice, knockdown/overexpression, Nfatc1 reporter, and bone resorption models

    PMID:35864959

    Open questions at the time

    • How Hey1 binding represses Nfatc1 transcription mechanistically unresolved
    • Relationship to the BRCC36 complexes unaddressed
11. 2016 Medium

    Identified a role in muscle regeneration whereby BABAM2 supports satellite-cell migration by protecting CXCR4 from SDF-1α-induced degradation.

    Evidence Knockout mice with muscle injury model, time-lapse and chemotaxis assays, and CXCR4 immunoblotting

    PMID:26740569

    Open questions at the time

    • Molecular mechanism of CXCR4 stabilization not defined
    • Link to deubiquitinase complex activity untested

• How BABAM2's well-defined scaffolding role in nuclear/cytoplasmic deubiquitinase complexes mechanistically connects to its diverse tissue-specific functions (death-receptor signaling, p53/Mdm2, Hey1-Nfatc1, CXCR4 stabilization) remains unresolved.
• No structural model linking the UEV domain to the multiple receptor and transcription-factor partners
• Whether the same molecular activity underlies all reported roles is untested